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ology and cell biology, which are also of great interest and
practical benefit to medicine, has stimulated scientists of
various disciplines worldwide to become involved in
kallikrein-kinin research. Included are also those scien-
tists working on numerous regulatory or mediator sys-
tems cooperating with the kallikrein-kinin system. In this
issue of Biological Chemistry, leading experts in their par-
ticular field have reviewed present knowledge or reported
recent developments in topics of major interest, especial-
ly regarding the regulation, intracellular signaling events
and functions of kinin receptors, the regulatory or thera-
peutic potential of kinin receptor antagonists in biology,
pharmacology and medicine, as well as special cellular
events associated with the kallikrein-kinin system. In
view of the present political and economic pressure to
produce applicable results in science in a minimum of
time, we would like to mention that only recently, i. e. 70
years after the discovery of the kininases, was the thera-
peutic effectiveness of a drug for coronary heart disease
proven in extensive clinical studies that were based on
the seminal discoveries outlined above (The HOPE Study
Investigators, 1996; The Heart Outcome Prevention Eval-
uation Study Investigators, 2000). This drug, an an-
giotensin I converting enzyme inhibitor, simultaneously
blocks the degradation of kinins and the generation of
angiotensin II, two tissue hormones exhibiting opposite
biological or pharmacological effects.
A sense of tradition, combined with the concentration
in Munich of research activities associated with the
kallikrein-kinin system, kept the memory of the two scien-
tists from the University of Munich, Emil-Karl Frey and Eu-
gen Werle, alive and led to the establishment of the ‘E.K.
Frey-E. Werle Foundation of the Henning L. Voigt Family’
in 1985 (see Figure 2). The purpose of the Foundation is
the promotion of science and research in the fields of car-
diology, hemostasiology and metabolism, to elucidate the
functional role of the kallikrein-kinin system as well as of
systems communicating with it. The Foundation bestows
two types of awards: The Commemorative E.K. Frey-E.
Werle Medal in Gold, to honor outstanding achievements
in the kallikrein-kinin and related fields, and the E.K. Frey-
E. Werle Promotion Prize for younger scientists who have
made important contributions to contemporary research.
The Honorary Membership Medal of the Foundation in
Silver is awarded to scientists who contributed to our
knowledge on the role of the kallikrein-kinin system in
health and disease over decades so that their research
activities have significantly influenced the development in
the field, and also to scientists or persons with special
merits regarding the objectives of the Foundation.
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This volume contains selected contributions from an in-
ternational conference held June 1 – 3, 2000, in Munich,
which was devoted to the 75th anniversary of the discov-
ery of kinins. The surgeon Emil-Karl Frey, a scholar of the
famous ‘Geheimrat’ Ferdinand Sauerbruch, observed in
1925 a considerable reduction in blood pressure when he
injected the urine of humans into dogs. Unlike many oth-
er contemporary scientists he did not attribute this effect
to a toxic action of urine, but to the specific response to a
substance with potential biological functions (Frey, 1926;
Frey and Kraut, 1926): ‘It is a substance that probably
originates from several organs, is eliminated by the kid-
neys and has a pronounced cardioactive and vasoactive
effect; a substance that is assigned the role of a hormone
in the organism’. This F-substance was later termed
kallikrein (Kraut et al., 1930). Ten years later Eugen Werle
(Werle et al., 1937) found out that kallikrein is a proteolyt-
ic enzyme (‘ferment’), which liberates the biologically
highly active, basic polypeptide ‘DK’ or kallidin from a
blood plasma protein, kallidinogen or kininogen. Hence,
kallidin was the first of the basic tissue hormones, later
known as kinins, to be described in greater detail, espe-
cially regarding its manifold pharmacological effects
(Frey et al., 1950). Werle also observed for the first time ir-
reversible ‘fermental degradation’ of kallidin by ‘kininas-
es’ and identified the kininases as peptidases (Werle and
Grunz, 1939). Hence, the fundament of the system that
we refer to today as the kallikrein-kinin system was set up
by Frey, Kraut and Werle (see Figure 1).
The vital importance of the kallikrein-kinin system for
fundamental mechanisms in biochemistry, patho/physi-
ology, pharmacology, and more recently in molecular bi-
Fig. 1 The Surgeon Emil-Karl Frey (left), the Chemist Eugen
Werle, and the Physiologist Heinrich Kraut (right).
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We are very grateful to the SFB 469 of the LMU Mu-
nich, the institutions of the organizers of the conference
‘KININS 1925 – 2000 Munich’, and especially the E.K.
Frey-E. Werle Foundation of the Henning L. Voigt family
for continuous support of research in the kallikrein-kinin
and related fields, and last but not least to the partici-
pants of the conference who submitted articles for a spe-
cial highlight issue on kinins.
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Fig. 2 The Family of the Founder Henning L. Voigt (right), his son
Jason and Mrs. Gerda Voigt-Garcia.
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